Key result
Burden of treatment variables and multimorbidity had no significant effect on oral oncolytic agent temporary stoppages, whereas female sex and kinase inhibitor use increased the likelihood of stoppages.
Why the study?
The study was conducted to examine the effect of burden of treatment and multimorbidity on the relationship between baseline characteristics and oral oncolytic agent temporary stoppages.
Does an adherence and symptom management intervention reduce temporary oral oncolytic agent stoppages in patients with cancer?
RCT (n=272)
randomly assigned
Yes
Does an adherence and symptom management intervention reduce temporary oral oncolytic agent stoppages in patients with cancer?
Burden of treatment and multimorbidity did not significantly affect temporary stoppages of oral oncolytic agents, though women and patients on kinase inhibitors were at higher risk.
Answers are grounded in this paper and cite their sources.
Burden of treatment and multimorbidity showed no effect on OOA stoppages; leaves open other drivers of adherence for prospective confirmation.
OBJECTIVES: To examine the effect of burden of treatment and multimorbidity on the relationship between baseline characteristics and oral oncolytic agent (OOA) temporary stoppages. SAMPLE & SETTING: 272 patients newly prescribed OOAs at six National Cancer Institute-designated comprehensive cancer centers. METHODS & VARIABLES: Patients were randomly assigned to an adherence and symptom management group or a usual care/control group. Temporary OOA stoppages, symptom interference, OOA regimen complexity, and multimorbidities were explored. Data were collected at four-week intervals for 12 weeks. RESULTS: Burden of treatment variables and multimorbidity had no significant effect on OOA temporary stoppages. Women and those prescribed kinase inhibitors were significantly more likely to experience a temporary stoppage. IMPLICATIONS FOR NURSING: Oncology nurses are in a crucial position to educate patients on self-management of OOAs and symptoms. Nurses should be aware of patients who may be more susceptible to severe symptoms, including those with multimorbidities. Future research is needed to better understand OOA stoppages and factors associated with preventing stoppages.
No takes yet. Share an insight, caveat, or question.
Vachon et al. (2019) conducted an RCT in Cancer (n=272). Adherence and symptom management vs. Usual care/control group was evaluated on Oral oncolytic agent (OOA) temporary stoppages. Burden of treatment variables and multimorbidity had no significant effect on oral oncolytic agent temporary stoppages, whereas female sex and kinase inhibitor use increased the likelihood of stoppages.
Synapse has enriched 10 related papers. Consider them for comparative context: